After a lucrative IPO in September, Richmond-based BioAge is seeing its biotech fortunes shift with its stock falling over 70 ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.

Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...

With so many weight loss medications on the market, it's easy to feel overwhelmed by the options. From brand-name heavy ...

In the fierce race to dominate the weight loss drug market, global pharmaceutical giant Eli Lilly announced on Wednesday that ...

Eli Lilly (LLY) announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound provided a 47% greater relative weight loss compared to Wegovy. On average, ...

Lilly's Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

Eli Lilly ( NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly's weight ...